Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124897 | 0.95 | ELANE (0.43) | ELANECETPTRPA1CYP3A4ALDH1A1 | |
| SCHEMBL125575 | 0.79 | ALOX15 (0.41) | ELANETRPA1CYP3A4ADORA2BADORA1 | |
| SCHEMBL10943835 | 0.78 | ELANE (0.50) | ELANECETPLMNA | |
| SCHEMBL10950684 | 0.78 | ELANE (0.50) | ELANECETPLMNA | |
| SCHEMBL126289 | 0.78 | ALOX15 (0.41) | ELANETRPA1CYP3A4ALDH1A1LMNA | |
| SCHEMBL15547130 | 0.76 | CYP3A4 (0.49) | CYP3A4ALDH1A1CA2LMNATSHR | |
| SCHEMBL15548676 | 0.74 | KDM4E (0.46) | ELANECYP3A4ALDH1A1CA2LMNA | |
| SCHEMBL15548954 | 0.72 | PRSS1 (0.49) | CYP3A4ALDH1A1CA2LMNATSHR | |
| SCHEMBL15547939 | 0.71 | PTGS2 (0.52) | CYP3A4ALDH1A1CA2TSHRHSD17B10 | |
| SCHEMBL6900485 | 0.71 | CYP1A2 (0.41) | CETPCYP3A4ALDH1A1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428577-B1 | Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters | EASTMAN CHEM CO (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2428577-A1 | Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters | EASTMAN CHEMICAL COMPANY (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2155886-B1 | Cosmetic use of inhibitors of tyrosinase | EASTMAN CHEM CO (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110129430-A1 | HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2011-06-02 | — | — | US | disclosed |
| US-20080306144-A1 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | EASTMAN CHEMICAL COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306144-A1 | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | TYR, TH, HAAO | ELANE 195/4885CETP 913/4885TRPA1 4350/4885 |
| US-20110129430-A1 | HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS | TYR, TH, HAAO | ELANE 195/4885CETP 913/4885TRPA1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.